Beigene Ltd
ONC269.630USD
-6.899-2.50%
Handelsschluss 06/13, 16:00（ET）Kurse um 15 Minuten verzögert
26.72BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Beigene Ltd Unternehmen
BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.
Unternehmensinformationen
BörsenkürzelONC
Name des UnternehmensBeigene Ltd
IPO-datum- -
Gegründet am2010
CEOMr. John Victor Oyler
Anzahl der mitarbeiter11000
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addressec/o Mourant Governance Services (Cayman)
StadtGRAND CAYMAN
BörseThe Toronto Stock Exchange
LandCayman Islands
PostleitzahlKY1-1108
Telefon13459494123
Websitehttps://www.beigene.com/
BörsenkürzelONC
IPO-datum- -
Gegründet am2010
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
Aktionärsstatistik
Aktualisiert: Tue, Jun 3
Aktualisiert: Tue, Jun 3
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.29%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.65%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.10%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
21.70%
Corporation
17.31%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.86%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.68%
Institutionelle Beteiligung
Aktualisiert: Mon, Jan 20
Aktualisiert: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
559
66.79M
67.51%
+1.06M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Jun 2
Aktualisiert: Mon, Jun 2
Name
Anteil
First Trust NYSE Arca Biotechnology Index Fund
3.51%
Innovator IBD 50 Fund ETF
3.07%
Tema Oncology ETF
2.94%
Virtus LifeSci Biotech Products ETF
2.51%
VanEck Biotech ETF
2.23%
Global X Aging Population ETF
2.05%
iShares Health Innovation Active ETF
1.51%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.17%
ProShares Ultra Nasdaq Biotechnology
1.17%
Mehr Anzeigen
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.51%
Innovator IBD 50 Fund ETF
Anteil3.07%
Tema Oncology ETF
Anteil2.94%
Virtus LifeSci Biotech Products ETF
Anteil2.51%
VanEck Biotech ETF
Anteil2.23%
Global X Aging Population ETF
Anteil2.05%
iShares Health Innovation Active ETF
Anteil1.51%
iShares Biotechnology ETF
Anteil1.42%
Invesco Nasdaq Biotechnology ETF
Anteil1.17%
ProShares Ultra Nasdaq Biotechnology
Anteil1.17%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
